Susquehanna International Group’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Buy
71,400
+44,700
+167% +$1.29M ﹤0.01% 5901
2025
Q4
$663K Sell
26,700
-74,800
-74% -$1.5M ﹤0.01% 8158
2025
Q3
$1.65M Buy
101,500
+71,100
+234% +$1.01M ﹤0.01% 6201
2025
Q2
$399K Sell
30,400
-52,000
-63% -$750K ﹤0.01% 9698
2025
Q1
$1.81M Buy
82,400
+18,100
+28% +$475K ﹤0.01% 5748
2024
Q4
$1.72M Sell
64,300
-44,200
-41% -$1.41M ﹤0.01% 5657
2024
Q3
$2.9M Buy
+108,500
New +$2.16M ﹤0.01% 4599

Other funds holding EWTX

Susquehanna International Group's EWTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Edgewise Therapeutics (EWTX) stake by 62% in Q1 2026, selling an estimated $1.26M and leaving 26,674 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #8350.

Susquehanna International Group first reported a position in EWTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $5.35M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Susquehanna International Group held 26,674 shares of Edgewise Therapeutics worth $840K as of Q1 2026.
  • Susquehanna International Group sold 43,522 Edgewise Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Edgewise Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8350 holding.
  • Susquehanna International Group first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Susquehanna International Group's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.